<DOC>
	<DOCNO>NCT02518048</DOCNO>
	<brief_summary>The purpose study evaluate anti-psoriatic effect LEO 90100 aerosol foam compare Betesil® medicate plaster</brief_summary>
	<brief_title>A Psoriasis Plaque Test Trial With LEO 90100 Compared Betesil® Patients With Psoriasis Vulgaris</brief_title>
	<detailed_description>The product apply 6 test site ( product 3 test site ) daily 6 day week ( except Sundays ) 4 week . The application sit product determine accord random assignment . Depending size psoriasis plaque , 2 4 test site locate within plaque ; treatment assignment do pair-wise .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Connective Tissue Diseases</mesh_term>
	<criteria>Signed date informed consent obtain Subjects diagnosis psoriasis vulgaris preferably three lesion ( plaque ) locate arm , leg and/or trunk least two lesion ( plaque ) locate arm , leg and/or trunk . For subject three lesion , lesion must size suitable accommodate 2 test site ( test site area 5 cm2 , distance two test site least 2 cm ) . For subject two lesion , one lesion must size suitable accommodate 4 test site , lesion must accommodate 2 test site . Age 18 year Outpatients Female subject must either nonchildbearing potential , i.e . postmenopausal confirm clinical history sterility ( e.g . subject without uterus tubal ligation ) , childbearing potential provide confirmed negative pregnancy test prior trial treatment rule pregnancy . Female subject breast feed Systemic treatment biological therapy , whether market , possible effect psoriasis vulgaris within follow time period prior randomisation : Etanercept within 4 week prior randomisation trial Adalimumab , infliximab within 8 week prior randomisation trial Ustekinumab within 16 week prior randomisation trial Other product within 4 weeks/5 halflives prior randomisation trial ( whichever longer ) Systemic treatment therapy biologicals , potential effect psoriasis vulgaris ( e.g. , corticosteroid , retinoids , immunosuppressant ) within 4week period prior randomisation trial Subjects use phototherapy within follow time period prior randomisation trial : PUVA : 4 week UVB : 2 week Subjects use one follow topical drug treatment psoriasis within 4 week period prior randomisation trial : Potent potent ( WHO group IIIIV ) corticosteroids Subjects use one follow topical drug treatment psoriasis within 2 week prior randomisation trial : WHO group III corticosteroid ( except use treatment scalp and/or facial psoriasis ) Topical retinoids , Vitamin D analogue , Topical immunomodulators ( e.g . calcineurin inhibitor ) , Tar product , Salicylic acid Subjects use emollient select plaque within 1 week randomisation trial Initiation , expect change concomitant medication may affect psoriasis vulgaris ( e.g. , beta blocker , antimalarial drug , lithium ACE inhibitor ) within 2 week prior randomisation trial Subjects current diagnosis guttate , erythrodermic , exfoliative pustular psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>